14
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Naltrexone for treatment of impaired awareness of hypoglycemia in type 1 diabetes: A randomized clinical trial.

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Impaired awareness of hypoglycemia (IAH) is a limiting factor in the treatment of type 1 diabetes (T1D) and is a challenging condition to reverse. The objective of this study was to test the hypothesis that naltrexone therapy in subjects with T1D and IAH will improve counterregulatory hormone response and recognition of hypoglycemia symptoms during hypoglycemia.

          Related collections

          Author and article information

          Journal
          J. Diabetes Complicat.
          Journal of diabetes and its complications
          Elsevier BV
          1873-460X
          1056-8727
          September 9 2015
          : 29
          : 8
          Affiliations
          [1 ] Division of Endocrinology and Diabetes, Department of Medicine, University of Minnesota, Minneapolis, MN, United States. Electronic address: mohee002@umn.edu.
          [2 ] Center for Magnetic Resonance Research, Department of Radiology, University of Minnesota, Minneapolis, MN, United States.
          [3 ] Division of Endocrinology and Diabetes, Department of Medicine, University of Minnesota, Minneapolis, MN, United States.
          [4 ] Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, United States.
          Article
          S1056-8727(15)00349-9 NIHMS780434
          10.1016/j.jdiacomp.2015.08.004
          4871128
          26345338
          ade16136-ef6f-4fe0-962f-ea415ee893a5
          History

          Hypoglycemia,HAAF,Impaired awareness of hypoglycemia,Naltrexone,Opioid antagonists,Type 1 diabetes

          Comments

          Comment on this article